Discovery Life Sciences
Discovery Life Sciences is the premier provider of biospecimen solutions to the pharmaceutical, biotechnology, and diagnostics industries. Water Street merged three highly complementary businesses – Conversant Bio, Discovery Life Sciences, and Folio Bio to create the company in 2018. The combination of Discovery’s scientific expertise, sample quality and breadth, and customized lab services are unmatched in the industry. It operates the largest biorepository of more than 10 million specimens and offers customized services that support clients with accelerating the discovery, research and development of novel biomarkers, drug candidates, and diagnostics. Water Street tapped our industry network to recruit Glenn Bilawsky, who has more than 30 years of experience in the pharmaceutical and contract research industries, as Discovery’s Chief Executive Officer.
Glenn P. Bilawsky
Chief Executive OfficerWork with us
Water Street recruited Glenn P. Bilawsky to serve as Chief Executive Officer of Discovery Life Sciences. He brings more than three decades of experience in pharmaceuticals, contract research services, and health economics. Since 2000, Glenn has established and sustained the aggressive growth of four companies that ranged in size from 20 employees to more than 4,000 worldwide; these included privately held companies and a division of UnitedHealth Group. He has participated in the acquisition of over 30 companies and the successful sale of three. Prior to joining Discovery Life Sciences, Glenn was CEO at Precision Health Economics, the i3 division of UnitedHealth Group, and INC Research, now Syneos Health. He held executive positions at Quintiles, Inc. and Pharmaco LSR, now part of PPD, Inc. Glenn started his pharmaceutical career in at McNeil Pharmaceutical, a division of Johnson and Johnson. Glenn holds a master’s in business administration in Marketing/Management.